000 02330nim a2200529 a 4500
001 HST8179
003 UkLoHST
006 m o h
007 cr nna||||||||
007 sr |mnnnnnzne|
008 200704s2020 enk|||||o||h||||||||eng d
028 5 0 _a8179
_bHenry Stewart Talks
035 _a(UkLoHST)4323
040 _aUkLoHST
_beng
_cUkLoHST
100 1 _aShankar-Hari, Manu,
_u(NIHR Clinician Scientist & Consultant in ICM, Guy's and St Thomas' NHS Foundation Trust., UK)
_4spk
245 1 0 _aConvalescent plasma therapy as a treatment for COVID-19
_h[electronic resource] /
_cManu Shankar-Hari.
260 _aLondon :
_bHenry Stewart Talks,
_c2020.
300 _a1 online resource (1 streaming audio file (15 min.)).
490 1 _aInterviews on Covid-19,
_x2056-452X
500 _aAudio interview.
500 _aTitle from title frames.
505 0 _aContents: What is convalescent plasma therapy -- Does this treatment confer long-lasting immunity? -- Mechanism of action of therapeutic antibodies -- Counterindications with plasma transfusions -- The need for lengthy clinical trials -- Preliminary assessment of convalescent plasma therapy in a clinical trial -- When might this treatment be approved, and how fast can it be delivered?.
506 _aAccess restricted to subscribers.
538 _aMode of access: World Wide Web.
650 0 _aBlood plasma.
650 0 _aClinical trials.
650 0 _aCoronavirus infections
_xTreatment.
650 0 _aCOVID-19 (Disease)
_xTreatment.
650 0 _aViral antibodies.
650 2 _aAntibodies, Viral
_xadministration & dosage.
650 2 _aAntibodies, Viral
_xblood.
650 2 _aAntibodies, Viral
_xtherapeutic use.
650 2 _aBetacoronavirus
_ximmunology.
650 2 _aBlood Donors.
650 2 _aClinical Trials as Topic.
650 2 _aCoronavirus infections.
650 2 _aCOVID-19
_xblood.
650 2 _aCOVID-19
_ximmunology.
650 2 _aCOVID-19
_xtherapy.
650 2 _aImmunization, Passive.
650 2 _aPneumonia, Viral
_xprevention & control.
650 2 _aPneumonia, Viral
_xtherapy.
650 2 _aSARS-CoV-2.
830 0 _aHenry Stewart talks.
_pBiomedical & life sciences collection.
_pInterviews on Covid-19.
856 4 0 _uhttps://hstalks.com/bs/4323/
856 4 2 _uhttps://hstalks.com/bs/p/1060/
_3Series
999 _c75997
_d75997